APS versus LAC

This version of the course is no longer available.
Need multiple seats for your university or lab? Get a quote
The page below is a sample from the LabCE course . Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about (online CE course)
APS versus LAC

There are good tests that specifically measure auto-antibodies against the most common phospholipid protein targets seen in APS. These tests include:
  • Anti-cardiolipin IgG
  • Anti-cardiolipin IgM
  • Beta-2 glycoprotein 1 IgG
  • Beta-2 glycoprotein 1 IgM
But there are also less specific coagulation tests (clotting tests) that are used to help uncover a lupus anticoagulant. Oftentimes, a LAC is discovered when a patient has a prolonged PT or aPTT but no factor deficiency. So there are two different scenarios to consider: one is when a patient presents with recurrent thrombi or fetal loss. In this scenario specific antibodies to cardiolipin and beta-2 glycoprotein 1 will be ordered. The second scenario is when a patient has an unexplained prolonged clotting time in vitro (in the lab) but has no bleeding issues. In this later case the LAC is often discovered as an incidental finding. When present, a LAC will inhibit all the contact activation pathway factors (factors VIII, IX, XI and XII). Remember that a LAC will cause increased clotting in vivo (in the patient), but decreased clotting in vitro (in lab tests).